DELRAY BEACH, Fla., Sept. 10, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Revenue Cycle Management (RCM) Market is projected to reach USD 132.06 billion by 2031 from USD 73.61 billion in 2026, at a CAGR of 12.4% during the forecast period.

Browse 436 market data Tables and 50 Figures spread through 378 Pages and in-depth TOC on "Revenue Cycle Management (RCM) Market - Global Forecast to 2031"

Revenue Cycle Management Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 73.61 billion

- 2031 Projected Market Size: USD 132.06 billion

- CAGR (2026–2031): 12.4%

Revenue Cycle Management Market Trends & Insights:

- By region, the North American revenue cycle management market dominated, with a 40.0% share in 2025.

- By enterprise size, the small & medium-sized enterprises segment is expected to register the fastest growth in the market, at a CAGR of 13.0%.

- By delivery mode, the on-premises segment holds the largest share of 56.4% in 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153900104

The global revenue cycle management (RCM) market is propelled by the rising volume of healthcare data, the shift toward value-based reimbursement, and the growing emphasis on financial transparency. Increasing adoption of cloud-based RCM platforms, interoperability requirements, and the demand for real-time claims visibility are further accelerating market growth. Additionally, workforce shortages and administrative inefficiencies are prompting healthcare organizations to invest in digital RCM tools and outsourced services to ensure faster, error-free reimbursement cycles.

The RCM landscape is being reshaped by advancements in AI-driven automation, predictive analytics, and natural language processing (NLP) for real-time coding and claims adjudication. The integration of FHIR-based interoperability standards is enabling seamless data exchange between payers and providers, enhancing transparency and reducing denials. Regulatory initiatives such as the No Surprises Act and updates to CMS reimbursement models are driving greater accountability and pricing transparency. Together, these technological and regulatory shifts are pushing healthcare organizations toward intelligent, compliant, and patient-centric revenue cycle models that emphasize accuracy, efficiency, and end-to-end financial visibility.

The healthcare providers segment accounted for the largest share of the revenue cycle management market in 2025.

Healthcare providers represent the largest end-user segment in the revenue cycle management (RCM) market due to their pressing need to manage complex reimbursement workflows, multi-payer coordination, and clinical data integration. Large hospital networks and integrated delivery systems are deploying enterprise-grade RCM suites to consolidate disparate billing systems and manage denials across multiple specialties. In markets like the US and Canada, provider adoption is further driven by rising claim denial rates, payer audits, and CMS-driven documentation mandates. Advanced providers are also leveraging AI-assisted coding, robotic claims processing, and predictive denial analytics to improve revenue integrity and shorten reimbursement cycles.

The AI-enabled RCM solutions segment is expected to show the fastest growth in the revenue cycle management market, by technology maturity.

AI-enabled RCM solutions represent the fastest-growing technology segment in the revenue cycle management market, as healthcare organizations increasingly leverage artificial intelligence to enhance accuracy, speed, and decision-making across billing workflows. AI-powered tools are being adopted for predictive denial management, automated coding, claims scrubbing, and payment forecasting, significantly reducing manual intervention and revenue leakage. Leading vendors such as Optum, Oracle Health, Infinix Healthcare, Plutus Health, Advanced Data Systems, and R1 RCM, etc, are embedding machine learning and natural language processing into RCM platforms to enable real-time insights, automate complex administrative tasks, and optimize reimbursement efficiency across large, multi-entity healthcare systems.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=153900104

North America dominated the revenue cycle management market in 2025.

In 2025, North America dominated the global revenue cycle management (RCM) market, driven by the region's mature healthcare infrastructure, early adoption of advanced IT systems, and strong regulatory oversight mandating accurate billing and data transparency. The US leads with its highly fragmented payer landscape, where providers increasingly rely on AI- and analytics-powered RCM platforms to manage denials, automate coding, and optimize reimbursements. Ongoing CMS initiatives promoting interoperability, the expansion of value-based payment models, and the growing preference for outsourced RCM partnerships with players like Optum, R1 RCM, and Conifer Health Solutions further strengthen regional leadership. Additionally, integrating RCM with EHR, ERP, and patient engagement systems enhances operational efficiency and cash flow visibility across large hospital networks.

Key Players

Leading players in the Revenue Cycle Management companies include Optum, Inc. (US), Epic Systems Corporation (US), Oracle (US), McKesson Corporation (US), Solventum (US), Experian Information Solutions, Inc. (Ireland), R1 RCM Inc. (US), Medical Information Technology, Inc. (US), Conifer Health Solutions. (US), Veradigm LLC (US), eClinicalWorks (US), Cognizant (US), athenahealth, Inc. (US), The SSI Group, LLC (US), Huron Consulting Group Inc. (US), AdvancedMD, Inc. (US), GeBBS (US), IKS Health (India), CareCloud, Inc. (US), MEDHOST (US), Greenway Health, LLC (US), FinThrive (US), Plutus Health (US), Omega Healthcare Management Services (India), and Vee Healthtek, Inc. (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=153900104

Revenue Cycle Management Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The revenue cycle management market is seeing increasing investment activity, driven by AI-native automation, denial management, and consolidation across claims and payment platforms. Funding has increasingly targeted platforms that can automate coding, prior authorization, and denial prevention rather than single-task billing tools. In July 2026, Candid Health (US) raised USD 120 million in Series D funding, tripling its valuation from its February 2025 Series C round, to scale its AI-driven claims automation platform. In March 2026, Adonis (US) raised USD 40 million in Series C funding, bringing its total funding to more than USD 95 million, to expand its AI orchestration platform for revenue cycle operations.

Revenue Shift Context

The market shows a shift from manual, labor-intensive billing toward AI-enabled coding, predictive denial management, and autonomous claims adjudication. The global revenue cycle management market is projected to increase from USD 73.61 billion in 2026 to USD 132.06 billion by 2031, at a CAGR of 12.4%, with nearly two-thirds of providers already using AI somewhere in their revenue cycle, according to Experian Health's 2026 State of Claims survey. Investment is increasingly moving toward agentic AI, real-time claim adjudication, and end-to-end orchestration platforms. In May 2026, Innovaccer acquired CaduceusHealth to extend its Flow platform into full-stack, AI-native revenue cycle management for ambulatory care providers.

Mergers and Acquisitions

M&A activity in revenue cycle management is increasingly focused on acquiring AI-native coding, denial analytics, and clinical documentation intelligence capabilities. Major transactions have targeted mid-cycle clinical intelligence, patient access, and payment analytics platforms as established RCM vendors seek to expand agentic AI capabilities and strengthen end-to-end automation.

REVENUE CYCLE MANAGEMENT MARKET: MERGERS & ACQUISITIONS, JANUARY 2025–AUGUST 2026

Company Revenue Share Details

The revenue cycle management market remains competitive, with diversified health-tech leaders competing alongside specialized RCM vendors. Optum, Waystar, and Solventum maintain strong positions through large installed provider bases and integration of AI into claims, coding, and denial workflows. According to UnitedHealth Group, Optum Insight reported USD 19.4 billion in full-year 2025 revenues, while Waystar reported USD 1.1 billion in full-year 2025 revenue, up 17% year-over-year. Solventum's Health Information Systems segment, which includes its coding and RCM technology, accounted for 16.3% of the company's USD 8.33 billion in net sales in 2025. However, these figures reflect broader business segments rather than RCM software alone and should not be treated as individual market shares.

Browse Adjacent Market: Healthcare IT Market Research Reports &Consulting

See More Latest Medical Devices Reports:

Healthcare IT Market by Solution [Clinical (EHR, PHM, PACs & VNA, Telehealth, RCM, CDSS, LIS), Nonclinical (Analytics, RCM, Pharmacy, Interoperability), Service (Claim, Billing, Supply)], End User (Hospital, ASC, Pharmacy, Payer) - Global Forecast to 2031

Healthcare Analytics Market by Type (Predictive, Diagnostic), Application (Claim, RCM, Fraud, Precision Health, RWE, Imaging, Supply Chain, Workforce, Population Health), End User (Payer, Hospital, ACO, ASC), AI, Market Insights, Trends - Forecast to 2031

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space.

The obesity treatment pipeline is rapidly evolving, with promising candidates such as RGT-075 (Regor Therapeutics), MET-002o (D&D Pharmatech/Pfizer), enicepatide (CT-388; Roche/Carmot Therapeutics), elecoglipron (AstraZeneca), and several other emerging therapies advancing next-generation approaches to weight management. These pipeline assets are being developed to broaden therapeutic options and potentially achieve greater and more sustained weight loss.

LAS VEGAS, Sept. 10, 2026 /PRNewswire/ -- The obesity therapeutics market is becoming increasingly concentrated around an Eli Lilly–Novo Nordisk duopoly, with tirzepatide (ZEPBOUND) and semaglutide (WEGOVY) continuing to dominate the US branded treatment landscape. However, the competitive environment is evolving rapidly with the introduction of oral GLP-1 therapies. Novo Nordisk's oral WEGOVY surpassed 5 million cumulative US prescriptions within 30 weeks, while Eli Lilly's FOUNDAYO gained notable momentum among patients initiating oral obesity treatments by mid-2026.

Despite strong demand for GLP-1 therapies, treatment persistence remains a significant challenge in real-world settings. Approximately 65–68% of patients discontinue GLP-1 treatment within 12 months, with discontinuation rates reaching as high as 85% by 24 months. Key drivers include high out-of-pocket expenses, loss of insurance coverage, persistent gastrointestinal adverse events, and drug supply limitations. These real-world patterns underscore a considerable gap between treatment persistence observed in routine clinical practice and the comparatively lower discontinuation rates reported in controlled Phase III clinical trials.

Discover more about obesity drug market trends 2026 @ https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

The obesity treatment landscape is increasingly shaped by Novo Nordisk and Eli Lilly, whose leading incretin-based therapies have secured prominent positions in the market. Novo Nordisk's SAXENDA (liraglutide) and WEGOVY (semaglutide), together with Eli Lilly's ZEPBOUND (tirzepatide), form the cornerstone of the current pharmacological treatment landscape. Both companies are further expanding their competitive presence by advancing next-generation oral therapies and multi-agonist approaches aimed at addressing the evolving needs of patients with obesity.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that following its US approval and launch, orforglipron (FOUNDAYO) is positioned for fast market uptake, with its once-daily oral formulation offering a potentially differentiated and more convenient alternative to other obesity therapies.

The obesity pipeline comprises several promising therapies in mid- and late-stage development that could reach the market in the near term. The anticipated launch of emerging treatments, including Enicepatide (CT-388) by Roche, Survodutide by Boehringer Ingelheim, Retatrutide by Eli Lilly, CagriSema by Novo Nordisk, RGT-075 by Regor Therapeutics, MET-002o by D&D Pharmatech, Elecoglipron by AstraZeneca, and other pipeline candidates, is expected to further strengthen the obesity market and drive positive anti-obesity market growth.

Reflecting the rising prevalence of obesity and the substantial unmet medical needs associated with its long-term health consequences, the obesity market across the seven major markets, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately USD 16 billion in 2025. The market is projected to expand at a 27% CAGR during the forecast period through 2036, driven by the increasing prevalence of obesity, growing awareness and diagnosis, expanding access to anti-obesity treatments, advances in weight-management strategies, and the introduction of novel therapies offering improved efficacy, tolerability, and broader patient benefits.

Below, we highlight 7 promising obesity medications poised to reshape the future of the weight loss market.

Novo Nordisk's CagriSema

NDA Filed

Novo Nordisk is positioning CagriSema as a key next-generation cardiometabolic asset. The once-weekly injectable combines the long-acting amylin analog cagrilintide 2.4 mg with the company's blockbuster GLP-1 receptor agonist WEGOVY (injectable semaglutide 2.4 mg) for the treatment of obesity and type II diabetes (T2D). Novo Nordisk has already submitted CagriSema for U.S. approval in weight management, with an FDA decision anticipated in the fourth quarter of 2026. If approved, the therapy could provide the company with a new growth opportunity beyond its established semaglutide franchise.

Clinical data for CagriSema in obesity have been promising, with the therapy achieving the primary endpoints in two late-stage trials and supporting the FDA submission. In the Phase III REDEFINE 1 study, CagriSema delivered a mean weight reduction of 22.7% after 68 weeks, assuming treatment adherence among all participants, compared with 16.1% for WEGOVY and 11.8% for cagrilintide. Meanwhile, in the REDEFINE 2 study, which included adults with obesity or overweight and T2D, CagriSema resulted in a mean weight loss of 15.7%, assuming all participants adhered to treatment. Both studies showed statistically significant weight-loss improvements compared with placebo.

Novo Nordisk is also exploring whether higher doses could enhance CagriSema's efficacy in obesity. The company plans to initiate a Phase III study of high-dose CagriSema in the second half of 2026, combining cagrilintide 2.4 mg with Wegovy HD (injectable semaglutide 7.2 mg). Meanwhile, the Phase III REDEFINE 11 study is assessing the full weight-loss potential of the existing 2.4 mg/2.4 mg combination in adults with obesity, with results anticipated in the first half of 2027.

Eli Lilly's Retatrutide

Phase III

Retatrutide is an investigational, once-weekly triple hormone receptor agonist designed as a single molecule that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Eli Lilly is evaluating retatrutide across multiple Phase 3 clinical trials to assess its potential efficacy and safety in people with obesity or overweight and at least one weight-related medical condition, as well as in type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

In July 2026, Eli Lilly and Company reported positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide. Both studies achieved their primary endpoints, demonstrating substantial weight loss in adults with obesity and serious obesity-related complications, including type 2 diabetes and established cardiovascular disease.

In TRIUMPH-2 (n=1,152), retatrutide achieved its primary endpoint, with mean weight reductions of 12.7%, 19.1%, and 20.8% at the 4 mg, 8 mg, and 12 mg doses, respectively, at week 80, compared with 4.0% with placebo. TRIUMPH-3, which enrolled people with type 2 diabetes and obesity or overweight, also met its endpoints, showing significant improvements in body weight and HbA1c. Across the clinical development program, retatrutide has demonstrated mean weight loss of up to approximately 22.6% in adults with severe obesity.

Lilly stated that these results support a planned regulatory submission to the FDA in the first quarter of 2027. Retatrutide could potentially follow Lilly's dual GIP/GLP-1 receptor agonist tirzepatide, with the addition of glucagon-receptor activity to its mechanism of action.

Discover more about obesity drug development @ Anti Obesity Drug Trends

Roche/Carmot Therapeutics' Enicepatide (CT-388)

Phase III

Enicepatide (CT-388) is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist being developed for obesity and related comorbidities, including type 2 diabetes. The therapy incorporates biased signaling with minimal β-arrestin recruitment, which may support sustained receptor activity. In a Phase II trial, CT-388 demonstrated a placebo-adjusted weight loss of 22.5% at 48 weeks with the 24 mg dose, with no plateau observed. Additionally, 54% of participants achieved a BMI below 30 kg/m² compared with 13% receiving placebo. Its safety profile remained consistent with the established class, with no new safety signals identified.

AstraZeneca's Elecoglipron

Phase III

Elecoglipron is an investigational, once-daily oral small-molecule GLP-1 receptor agonist designed to mimic the action of naturally occurring GLP-1. By targeting GLP-1 receptors in the gut and hypothalamus through the brain-gut axis, it aims to regulate food intake and metabolic function. Its oral administration, scalability advantages over peptide-based therapies, and lack of food or fasting restrictions could potentially broaden treatment options for patients. AstraZeneca is evaluating elecoglipron both as a monotherapy and in combination regimens, with the potential to support the management of excess weight, associated health complications, and other interrelated diseases. Following positive Phase IIb results, AstraZeneca has advanced elecoglipron into an extensive Phase III development program.

To know more about new drug treatment for obesity, visit @ Future of Obesity Treatments

Boehringer Ingelheim/Zealand Pharma's Survodutide

Phase III

Survodutide is a dual glucagon/GLP-1 receptor agonist that activates both glucagon and GLP-1 receptors, which are involved in regulating key metabolic functions. As an investigational therapy, survodutide has not yet been approved for use, and its safety and efficacy have not been established.

Response Media launches RE:HEALTH to Address Pharma's $300 Billion Adherence Blind Spot¹

New health and life sciences practice debuts AdherenceIQ, an AI-powered platform that predicts patient adherence risk

ATLANTA, Sept. 10, 2026 /PRNewswire/ -- Medication nonadherence costs the U.S. healthcare system as much as $300 billion annually. Despite significant investments in awareness, patient acquisition, and new prescription generation, life sciences companies struggle to identify which patients will start/discontinue therapy and understand the emotional barriers driving those decisions.

Response Media today announced the launch of RE: HEALTH, a specialized health and life sciences practice built to help pharmaceutical and health brands close that gap.

Backed by decades of healthcare marketing expertise, RE: HEALTH combines behavioral science, privacy-compliant AI and advanced analytics to help brands identify the emotional barriers to treatment and translate that intelligence into engagement strategies that improve adherence, persistence and TRx growth.

"Medicine is an emotional decision but the industry has marketed it as a functional one," said Josh Perlstein, Response Media CEO. "We believe there is a smarter approach, and it begins with focusing on the human behind every treatment."

With the launch, the company is introducing AdherenceIQ, a proprietary, AI-powered behavioral intelligence platform that predicts and addresses therapy adherence risk before drop-off occurs.

Built on published adherence science, AdherenceIQ identifies the emotional and functional barriers preventing patients from starting or continuing therapy, predicts who is most likely to disengage and why, and recommends intervention strategies based on those barriers.

For chronic and rare disease therapies, where adherence and persistence are critical to patient outcomes and commercial performance, AdherenceIQ shifts the focus from measuring attrition to identifying patients at risk of disengaging while there is still an opportunity to intervene.

"Adherence is too often treated as a reminder problem," said Dr. Alvin Glay, chief strategy officer, RE:HEALTH. "But patients don't make decisions based on reminders. Concerns about side effects, necessity, distrust, and stigma all shape their decisions. We can now uncover those barriers early enough to intervene in a relevant, human way that not only improves patient outcomes but accelerates TRx growth."

About Response Media: Ad Age's Data & Insights Small Agency of the Year in 2025, Response Media is a performance marketing agency specializing in data-led CRM/CX strategy and media. The agency has worked with a range of healthcare brands including Bausch + Lomb, Mucinex, Enfamil, and WellStreet Urgent Care.

Source1 National Library of Medicine

SOURCE Response Media

Share this article

The article reviews how partial hospitalization programs provide structured mental health treatment and emotional stability without requiring inpatient hospitalization.

YOUNGSTOWN, Ohio, Sept. 10, 2026 /PRNewswire/ -- What does a partial hospitalization program involve, and when might it be recommended?

HelloNation has published an article featuring Gloris Griffin of Gloris Counseling Services LLC, explaining how PHP mental health services provide structured mental health treatment, group counseling, and skill-building activities for individuals needing more support than traditional outpatient counseling.

The article explains that mental health treatment needs vary significantly depending on symptom severity, emotional functioning, and the level of support required during recovery. While some individuals benefit from weekly outpatient counseling, others may need more intensive daytime care during periods of emotional instability or worsening symptoms. A partial hospitalization program, commonly called a PHP, offers one level of care designed to provide structured daytime support while still allowing participants to return home each evening.

One of the primary topics discussed throughout the article is how a partial hospitalization program differs from inpatient hospitalization and traditional outpatient counseling. According to the article, PHP mental health services are typically designed for adults who require more support than weekly therapy but do not need overnight hospitalization. In the Mahoning Valley, these programs often support individuals experiencing anxiety, depression, trauma-related concerns, mood disorders, or emotional crises that interfere with daily functioning.

The article explains that stabilization is one of the central goals of a partial hospitalization program. Individuals entering PHP mental health services may be struggling with emotional overwhelm, increased stress, worsening symptoms, or difficulty managing responsibilities at work, home, or within relationships. By providing structured mental health treatment throughout the week, PHP programs offer closer therapeutic support and clinical monitoring than traditional outpatient counseling alone.

Therapy is another major focus covered throughout the article. Participants in a partial hospitalization program may attend individual therapy sessions, group counseling, and therapeutic discussions designed to improve emotional regulation, communication, coping skills, and stress management. According to the article, group counseling may also help individuals feel less isolated by connecting them with others facing similar mental health challenges during recovery.

Skill-building activities are also emphasized as an important part of PHP mental health services. The article explains that many programs focus on teaching practical coping tools individuals can continue using after treatment. Skill-building activities may include mindfulness techniques, relapse prevention strategies, problem-solving methods, emotional regulation exercises, conflict resolution skills, and routines that support long-term emotional stability.

Medical and psychiatric oversight may also be incorporated into mental health treatment depending on the participant's needs. Some individuals within a partial hospitalization program may receive medication management, psychiatric evaluations, or ongoing symptom monitoring while participating in treatment. According to the article, having medical support available within the program may allow treatment providers to adjust care plans more quickly if symptoms change during recovery.

Unlike inpatient hospitalization, PHP mental health services allow participants to remain connected to their home environment and daily routines while receiving intensive daytime support. The article notes that returning home each evening may help individuals continue practicing coping strategies within familiar surroundings while maintaining connections with family and support systems.

The article also explains that a partial hospitalization program may be recommended following a recent mental health crisis, emotional setback, hospitalization, or period of increased instability. In some situations, outpatient counseling alone may no longer provide enough support to manage symptoms safely and effectively. Partial hospitalization programs often serve as a bridge between outpatient counseling and inpatient hospitalization by providing structured care without requiring overnight stays.

Family involvement is another topic discussed throughout the article. Mental health challenges can affect communication, routines, and relationships within the household, particularly during emotionally difficult periods. Some PHP mental health services may include educational sessions or family therapy components designed to strengthen support systems and improve understanding throughout the recovery process.

The article concludes by emphasizing that mental health treatment recommendations are highly individualized, meaning a partial hospitalization program may not be appropriate for every situation. Clinical evaluations often help determine whether PHP mental health services provide the right level of support based on current symptoms, functioning, and safety considerations. Access to structured mental health treatment options throughout the Mahoning Valley may help individuals and families feel more prepared when navigating periods of emotional instability.

What Partial Hospitalization Programs Involve & When They May Be Recommended features insights from Gloris Griffin, Counseling Expert of Youngstown, OH, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities. 

SOURCE HelloNation

Share this article

Together, the two family-owned organizations bring more than 180 years of combined experience serving the New York metropolitan area's commercial real estate, multifamily, healthcare, hospitality, industrial, institutional, and retail markets. By combining complementary expertise, the companies aim to simplify facility management while helping customers improve operational efficiency, maintain regulatory compliance, and reduce service coordination challenges.

The partnership is a strategic collaboration between two independent organizations and does not involve any change in ownership. Both companies will continue to operate independently while working together on opportunities where their services naturally align, providing customers with broader technical expertise and improved coordination across essential building systems.

Approved Oil provides comprehensive energy, plumbing, mechanical, and infrastructure support services that help keep critical building operations running efficiently. Service offerings include energy procurement, mobile boiler rentals, boiler/burner/domestic hot water heater installations, generator fuel piping certifications and local law compliance. Approved's 24/7 reliable service in combination with their vast energy solutions ensures uninterrupted operations and energy security.

RAEL Fire Protection specializes in the inspection, testing, maintenance, repair, installation, and compliance management of fire and life safety systems, supported by its proprietary RAEL-REDi™ technology platform. Their comprehensive service portfolio includes fire sprinkler systems, fire alarms & special hazard systems, kitchen fire suppression & hood cleaning services, as well as fire extinguisher sales/service. RAEL's specialized technical expertise combined with their advanced field service capabilities provides clients with a trusted single source for fire protection compliance and life safety solutions ensuring critical systems perform when they are needed most.

Together, the organizations will offer customers a more seamless experience by improving coordination across critical building systems, reducing administrative complexity, and providing trusted service partners capable of supporting a wider range of facility needs.

"Building owners and facility managers face increasing demands to maintain compliance, manage risk, and keep their facilities operating without interruption," said Oliver Israel, Vice President of Operations at RAEL Fire Protection. "By partnering with Approved Oil, we can better support our customers through coordinated service, complementary expertise, and a shared commitment to responsiveness and long-term relationships."

"Both organizations have built their reputations on reliability, technical excellence, and customer service," said Vincent Theurer, President and CEO of Approved Oil. "This partnership allows us to provide even greater value by connecting our expertise and delivering more comprehensive support for the buildings and facilities our customers depend on every day."

The companies expect the partnership to create new opportunities across commercial real estate, multifamily housing, healthcare, hospitality, retail, industrial, and institutional markets, helping customers streamline building operations while maintaining the highest standards of safety, compliance, and service.

SOURCE Approved Oil Company

Share this article

MADISON, Wis., Sept. 10, 2026 /PRNewswire/ -- Everlight Solar has once again earned recognition from Dane County's Climate Champions Program, receiving the designation of 2026 1-Star Champion in the Fleet category. The recognition highlights Everlight Solar's continued efforts to reduce emissions and transition its fleet toward clean energy.

The Dane County Climate Champions Program recognizes local organizations that take meaningful action to reduce greenhouse gas emissions and advance sustainability throughout the community. The Fleet category recognizes organizations working to adopt cleaner transportation options and reduce their reliance on fossil fuels.

Everlight Solar's 2026 recognition builds on several years of climate action and sustainability efforts. In 2025, the company earned Climate Champion recognition in the Fleet category after converting 25–50% of its vehicles to clean energy. Today, Everlight Solar operates 14 electric vehicles that support its teams as they travel to job sites, community events, and other locations throughout the region.

The company's commitment to sustainable fleet operations began well before its 2025 recognition. In 2023, Dane County named Everlight Solar an Emerging Climate Champion in Fleet Operations. In 2021, the company earned Climate Champion Catalyst status for helping others in the community take climate action.

"Our commitment to sustainability goes beyond the solar. It shapes how we operate our business every day," said William Creech, President and CEO of Everlight Solar. "We're proud to continue investing in clean-energy transportation and to see our team's efforts recognized by Dane County's Climate Champions Program."

Everlight Solar views its fleet as one part of a broader commitment to environmental responsibility. By incorporating electric vehicles into its operations, the company continues to reduce its environmental impact while supporting customers and communities throughout the region.

As Everlight Solar looks ahead, the company will continue exploring opportunities to expand its clean-energy efforts, reduce emissions, and contribute to a more sustainable Dane County and beyond.

About Everlight Solar

Everlight is a leading Midwest home services company, with operations in Wisconsin, Minnesota, Idaho, Nebraska, Iowa, Oregon, Utah, and Wyoming. What started as a solar company has grown into a provider of comprehensive solutions for homeowners through solar, roofing & exteriors, HVAC, and electrical services. With expert installation, exceptional service, and industry-leading warranties, Everlight makes it easier to improve your home's comfort, efficiency, energy independence, and curb appeal. See the difference at everlightsolar.com.

SOURCE Everlight Solar

Share this article

SINGAPORE, Sept. 10, 2026 /PRNewswire/ -- The fifth edition of the Leaders in Supply Chain Awards recognizes executives who are connecting strategy, technology, people, and execution to transform global value chains.

Alcott Global is announcing the Top 30 Leaders in Supply Chain of 2026, recognizing executives whose leadership is shaping stronger, smarter, and more responsible global supply chains.

Organized by global executive search firm Alcott Global, the Leaders in Supply Chain Awards celebrate senior executives who deliver measurable business impact while advancing innovation, resilience, digital transformation, sustainability, and people development across their organizations.

This year marks the fifth edition of the Awards, guided by the theme "Where Insight Connects the Dots."

In an environment defined by geopolitical uncertainty, technological disruption, shifting customer expectations, and growing pressure for responsible growth, the 2026 winners demonstrate the value of seeing the broader picture. Their leadership connects decisions, capabilities, and people across the organization to create resilience, accelerate transformation, and move businesses forward.

To be considered for the Leaders in Supply Chain Awards, nominees were required to meet stringent eligibility criteria:

- Hold a regional or global leadership role for at least 18 consecutive months

- Have end-to-end supply chain responsibility

- Work within a manufacturing organization with annual revenues exceeding USD 1 billion

Eligible candidates submitted detailed case studies outlining their leadership approach, business results, transformation programs, digital achievements, sustainability initiatives, and strategies for developing high-performing teams.

The final ranking was determined through a combination of:

- 75% independent Jury evaluation

- 25% peer voting by a global network of more than 2,000 senior supply chain executives

This methodology combines in-depth expert assessment with recognition from the wider supply chain community, ensuring a balanced, objective, and industry-reflective outcome.

The 2026 Jury brought together highly respected supply chain executives, former industry leaders, academics, authors, and transformation experts:

- Cliff Henson, Corporate Vice President Cloud Supply Chain and Engineering, Microsoft (2025 Award Winner)

- Mourad Tamoud, CSCO, Schneider Electric (2023–2024 Award Winner)

- Michael Corbo, Former CSCO, Colgate-Palmolive

- Kai Hoberg, Professor, SCM, Kühne Logistics University

- Cheryl Capps, Former CSCO, Corning

- Knut Alicke, Former Partner, McKinsey & Company, Advisor, Alcott Global

- Bart Derde, Former CSCO, Haleon

- Daniel Stanton, Founder and CEO, Mr. Supply Chain

- Deborah Dull, Author, Circular Supply Chain

- Radu Palamariu, Group CEO, Alcott Global

"For five years, these Awards have been dedicated to putting supply chain leaders under the spotlight they deserve. This year's winners demonstrate what it truly means to connect the dots between risk and resilience, strategy and execution, technology and decision-making, performance and responsibility, and leadership and legacy. Selected from 403 nominees and recognized through both independent Jury assessment and the voice of more than 2,000 industry peers, they represent the very best of modern supply chain leadership." - Radu Palamariu, Group CEO, Alcott Global

A Global Community of Supply Chain Leaders

The 2026 Awards attracted 403 nominees from 354 companies in 24 countries, reflecting the growing strategic importance of supply chain leadership across industries and regions.

From this highly competitive global pool, the Top 30 were selected for their ability to deliver meaningful results while leading their organizations through complex transformation.

Their case studies demonstrate how supply chain leaders are increasingly operating beyond traditional functional boundaries. They are influencing enterprise strategy, accelerating digital adoption, strengthening organizational resilience, developing future-ready talent, and helping businesses achieve sustainable long-term growth.

The winners were officially revealed during the virtual Leaders in Supply Chain Awards Gala on September 10, 2026.

The virtual ceremony brought together the global supply chain community to celebrate the winners' achievements, share perspectives from members of the independent Jury, and explore trends shaping the profession's future.

The 2026 Awards are supported by a global communications campaign spanning media relations, social media, community engagement, executive thought leadership, internal company recognition, and digital billboard features at Times Square in New York City. This campaign contributes to over 10 million impressions across global channels, 500+ press features, and wide visibility among Alcott Global's 3 million-strong audience.

Through this campaign, Alcott Global aims not only to celebrate the Top 30 winners, but also to amplify the role of supply chain leadership and inspire the next generation of executives shaping the world's value chains.

About Alcott Global

Alcott Global specializes in Executive Search and Leadership Advisory, with senior and board-level appointments across the end-to-end value chain and the PnL leadership spectrum, including CEOs, COOs, CSCOs, CFOs, Regional Managing Directors, and functional heads in planning, procurement, manufacturing, logistics, e-commerce, and supply chain operations.

In its mission to connect the value chain, Alcott Global convenes the global C-suite community through Makers & Movers, an invite-only forum for senior operators and enterprise leaders to connect, learn, and shape the future of value chain leadership together. The next edition will take place on April 28 to 29, 2027, in Zurich, Switzerland.

Through its technology arm, Supplify, Alcott Global enables corporations to identify and collaborate with cutting-edge logistics and supply chain technology providers to drive digital transformation.

Useful Links:

Alcott Global: https://alcottglobal.com

Leaders in Supply Chain Awards: https://gala.makersmovers.com

SOURCE Alcott Global

Share this article

Partnership integrates FanDuel odds and contextual markets into Real's live experience and creates a new way for FanDuel to connect with the next generation of sports fans

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Real App, the social sports app built around live play by play, real time stats and fan conversation, today named FanDuel, North America's Premier Online Gaming company, its first Official and Exclusive Sportsbook and Prediction Market Partner. The partnership will bring FanDuel odds and contextual markets directly into Real's live sports experience, giving members another way to understand, discuss and engage with the games they follow together on the platform. It will also position Real as a key destination for FanDuel to connect with the next generation of sports fans.

With over 1.5 million monthly active users, Real App has grown by making the live sports experience more immediate, interactive and social. Members use the app to track games and player performances in real time, react to key moments and debate what happens next with other fans.

"Our members are already using Real to track and discuss their bets in real time, and they've been requesting live odds," said Louis Antonelli, co-founder of Real. "Partnering with a trusted brand like FanDuel gives us a new layer of real-time sports data that we can surface in ways that are additive to the Real experience for members interested in betting."

FanDuel odds, markets and related visualizations will appear across Real game feeds, play level views, player performance screens, team box scores and other real time surfaces. Contextual markets will be surfaced around key game moments, with links that take eligible users directly to the applicable FanDuel experience. The design will pair familiar FanDuel odds presentation with Real's native interface, providing additional context without disrupting the experience that has made Real a natural gathering place for digitally first sports fans. The initial integration will begin for the start of the 2026 NFL season with a commitment to further integrations in the future.

"Some of the best parts of being a sports fan happen around the game - talking about what just happened, debating what comes next and sharing those moments with other fans," said Christian Genetski, President of FanDuel. "Real has built a great community around that experience. We're excited to work with them and find new ways to make FanDuel a natural part of how fans follow and engage with sports."

FanDuel and Real encourage fans to enjoy sports responsibly and are both committed to ensuring entertainment remains the primary focus of the experience. FanDuel odds and related features will be optional, and members will be able to disable them through their Real app settings. FanDuel is deeply committed to promoting responsible gaming and has developed comprehensive tools to help its customers set appropriate limits and engage safely with its platform.

Responsible gaming is a core principle of the odds and contextual markets experience for FanDuel and Real App. Features will be optional and can be disabled in the Real app settings. FanDuel is deeply committed to promoting responsible gaming and has developed comprehensive tools to help its customers set appropriate limits and engage safely with its platform. FanDuel and Real encourage fans to enjoy sports responsibly and are both committed to ensuring entertainment remains the primary focus of the experience.

About Real App

Real App (realapp.com) is the fastest-growing live social sports app, serving 1.1 million daily and 1.5 million monthly active users across 18 leagues. Fans use Real to follow every play, track player performances and discuss live moments. For many fans, Real is now the first place they learn what is happening in sports.

Engagement spikes around exciting live moments, with more than 70% of monthly active users returning on major game days and concurrent users surpassing 250,000 during close games. In the last 12 months, users have spent 4.8 billion minutes on the app. Real delivers 50 million notifications per day, and nearly 30% of monthly users actively comment.

Real covers 18 leagues across the NBA, NFL, NHL, MLB, WNBA, college sports, global soccer, tennis and more, with F1, horse racing and additional sports coming soon.

About FanDuel

FanDuel is the premier mobile gaming company in the United States. FanDuel consists of a portfolio of leading brands across mobile wagering including America's #1 Sportsbook, FanDuel Sportsbook; its leading iGaming platform, FanDuel Casino; its new prediction markets platform, FanDuel Predicts; its industry-leading horse racing and advance-deposit wagering, FanDuel Racing; and its daily fantasy sports product. FanDuel has a presence nationwide with offices in New York, Los Angeles, Atlanta and Jersey City, as well as in Canada, Scotland, Ireland, Portugal, Romania and Australia.

FanDuel is a subsidiary of Flutter Entertainment, the world's largest sports betting and gaming operator with a portfolio of globally recognized brands. Flutter Entertainment is traded on the New York Stock Exchange (NYSE: FLUT).

SOURCE FanDuel Group

Share this article

SHENZHEN, China, Sept. 10, 2026 /PRNewswire/ -- TCL has been named one of TIME's World's Best Companies for 2026, joining the annual list compiled by TIME and Statista based on an independent survey of 200,000 employees across more than 50 countries. TCL's selection on the prestigious list follows strong overall performance across employee satisfaction, financial strength, and ESG performance, reflecting TCL's long-term commitment to delivering sustainable growth driven by world-class talent.

The annual ranking assesses companies worldwide based on employee satisfaction, revenue growth, financial stability, and sustainability transparency, providing a comprehensive view of long-term performance.

For TCL, the recognition highlights its continued progress in three areas central to its global development: empowering people through an inclusive workplace, delivering high-quality growth through global operations, and embedding sustainability into its long-term strategy. As TCL marks its 45th anniversary this year, it remains committed to advancing technological innovation and creating sustainable value for customers and communities worldwide.

Empowering people through an inclusive global workplace

At TCL, people are the foundation of its global competitiveness. Attracting and developing world-class talent is core to TCL's global leadership, as it continues to build a diverse and inclusive workplace that supports employees' professional growth. As part of this, TCL continues to make the workplace a platform where talent can grow in step with the global industry by providing opportunities to work across markets and sectors. Beyond the workplace, TCL extends its commitment to inclusion and empowerment through global initiatives including #TCLforHer and #TCLYoung. Launched in 2021, #TCLforHer empowers women through technology, sports and education, while #TCLYoung, launched in 2022, encourages younger generations to pursue their passions, embrace creativity and challenge boundaries. TCL is also proud of its commitment to workplace safety, maintaining a record of zero major workplace safety incidents across its global operations in recent years.

Delivering high-quality growth through globalized operations

TCL continued to deliver strong financial performance in 2025 across its two major business groups. TCL Technology recorded revenue of approximately US$27 billion, up 11.7% year on year, while TCL Industries reported revenue of approximately US$24.9 billion, an increase of 13.8%. Also in 2025, overseas revenue exceeded US$24.93 billion, representing average annual growth of more than 18.3% over the past five years.

TCL has established a global manufacturing and R&D footprint spanning China, Vietnam, Poland, Mexico and Brazil, with operations in more than 160 countries and regions, strengthening its ability to serve customers worldwide and advance innovation.

Embedding sustainability into long-term growth

Sustainability is an integral part of TCL's long-term development strategy. TCL has published ESG and corporate social responsibility reports for 17 consecutive years and is a participant in the United Nations Global Compact (UNGC).

In 2025, TCL completed a US$200 million sustainability-linked syndicated loan—the first of its kind in the display panel industry—linking sustainability performance more closely with financial value. It is also advancing innovation in displays and clean energy, which are helping drive the global transition toward carbon neutrality.

"Being named one of TIME's World's Best Companies is another major recognition of TCL's commitment to technological leadership and responsible growth for 45 years," said a TCL representative. "Being a world leader means building lasting competitive advantages in both innovation and sustainable growth—and at the heart of these two lies our people and talent. As our global development continues, we look forward to more outstanding professionals joining TCL to develop their careers and make an impact globally."

About TCL

Founded in 1981, TCL—short for "The Creative Life"—is dedicated to empowering smarter, healthier lifestyles through next-generation experiences. Operating through two independent entities, TCL Industries and TCL Technology, TCL delivers innovative solutions spanning TVs, smartphones, audio products, smart home devices, display technologies, and clean energy.

Today, with 50 R&D centers and 47 manufacturing bases globally, TCL operates in over 160 countries and regions, reinforcing its position as a globally competitive smart technology brand. To further inspire greatness, TCL has become an official Worldwide Olympic and Paralympic Partner in the Home Audiovisual Equipment and Home Appliances category.

SOURCE TCL Technology Group Corporation

Share this article

JumpCloud Extends IAM to Protect the New Agentic Workforce

New Agentic IAM Capabilities Give IT Teams Visibility, Ownership, Access Control, and Governance for Autonomous Agents

LOUISVILLE, Colo., Sept. 10, 2026 /PRNewswire/ -- JumpCloud Inc. today announced the extension of its Agentic IAM capabilities. The platform now manages AI agents alongside human employees and devices. This gives IT teams the ability to govern agent access across data, apps, and everyday tasks.

As AI agents handle more company tasks, IT teams face a major challenge: Only 21% have adopted governance controls for them. They need to know which agents exist, who owns them, where they live, and when to cut off access. JumpCloud solves this by bringing humans, devices and agents into one place.

JumpCloud manages AI agents across three core areas:

- Visibility and ownership: Give IT teams a clear view of every AI agent and treat each one as a real identity. Every agent is tied to a human owner and tracked from creation to retirement. Agents registered in JumpCloud can't run without an assigned owner.

- Identity and access control: Connect every human and agent login to the automated tasks they perform. IT can trace every agent back to its human owner and track its actions. This helps reduce shadow AI and creates an automatic audit log.

- Governance and privileged access: Apply privileged access management (PAM) rules directly to AI agents. Agents get temporary, least-privilege access that automatically expires when the task is complete. This lets organizations safely connect AI to legacy systems without expensive upgrades.

"AI agents are changing how identity management works," said Joel Rennich, senior vice president, product management, JumpCloud. "These tools act fast. IT must know which agents exist, who owns them, and what they can touch. Agentic IAM brings that control into the same identity infrastructure companies already use for employees and devices."

"AI agents don't just access systems; they act inside them. That makes identity the control plane for AI security," said Rahul Kamdar, senior vice president of product at JumpCloud. "As agents become more autonomous, each needs a verifiable identity, explicit access boundaries, and governance across its lifecycle. JumpCloud is extending identity security beyond people and devices to agents, so organizations can accelerate AI adoption without creating a new security blind spot."

Key capabilities for secure agentic lifecycle management include:

- AI Agent Identity & Access: Give each AI agent a unique identity so admins can audit activity or revoke access instantly, without locking out the employee.

- Shadow AI to Secure MCP Connection: Automatically find hidden Model Context Protocol (MCP) setups and route them safely through the JumpCloud AI Gateway to stop shadow AI.

- Enforced Approved SaaS Access: Apply security, device trust, and access policies uniformly across every AI tool and app in your environment.

- PAM MCP Server: Replace risky shared API keys with a zero-setup PAM agent that locks permissions to isolated agent identities; coming before the end of Q4 2026.

By consolidating identity, device, and agent governance into a single console, JumpCloud enables organizations to scale AI in a secure and intelligent way. Learn more about our Agentic IAM Capabilities at jumpcloud.com.

About JumpCloud

JumpCloud® is the AI-powered unified IT management platform designed to secure the modern workforce. By consolidating identity, device, and access management, JumpCloud provides intelligent, secure IT that scales from human users to autonomous AI agents. We help organizations around the globe eliminate complexity and turn AI risk into an optimized advantage, ensuring the right people and agents have secure access to the right resources at all times.

Learn more: https://www.jumpcloud.com/

Follow us: Blog | Community | Podcast | X | LinkedIn | YouTube | Resources

Click here to get started with JumpCloud.

Contact

For JumpCloud

Josie Judy

[email protected]

SOURCE JumpCloud, Inc.

Share this article